Evolution has achieved some pretty amazing feats.

For too long, cancer treatment has been a double-edged sword – the very treatments designed to kill cancer cells often wrought havoc on healthy ones too.

Researchers at Duke University have demonstrated an app driven by AI that can run on a tablet to accurately screen for autism in children by measuring and weighing a variety of distinct behavioral indicators.

Everardo Macias, PhD, assistant professor of pathology at Duke University School of Medicine, explores the complexities of prostate cancer, the second leading cause of cancer death in men.

These genes encode proteins that help the bacterium to consume mucin, produce fatty acids, and regulate metabolism.

Decades of work by a series of Duke investigators yields new drug, patents and a startup company

Our cells are stressed and Duke biologist Gustavo Silva wants to help.

Moore, an assistant professor in neurology and member of the Duke Institute for Brain Sciences, has spent the past 15 years studying pain.

Cardiovascular disease is the number one killer of people in the United States and worldwide. Yet physicians often do not prescribe evidence-based medicines that could change those statistics.

Trudy Oliver, PhD, studies a type of cancer that has a 5-year overall survival rate of just 7%. Its biological drivers are different from most other cancers, so it's harder to develop targeted treatments. On top of that, research into this tumor is under-funded.

One of the latest targets in the study of healthy aging is the gut. Increasingly, research points to changes in the gut microbiome as a predictor of longevity and how well we age.

How our bodies sense our environment and react to it is a big question, and how we answer it can have important implications for drug development.

David G. Kirsch, MD, PhD, is leading a Duke Cancer Institute study on cancer biology and radiation response.

Eight interdisciplinary research projects

Experts know COVID-19 won't be the last major pandemic. What they don't know is where, or when, the next one will begin.

Gene enhancer from zebrafish senses damage, orchestrates repairs

Your body is in constant dialogue with its own fat, and fat talks a lot.

What if we could control genes linked to cancer to prevent them from developing into tumors in the first place? How can we extend our brain's ability to forestall damage from Alzheimer's disease? Is it possible to develop a vaccine for everything?

Duke University neurobiologist Lindsey Glickfeld is pushing the limits of brain plasticity.

Neurobiologist Chantell Evans Ph.D. wants to end neurogenerative disease.

The human placenta performs a delicate balancing act: it must let beneficial nutrients pass from the mother to the developing fetus, but block harmful pathogens from making the same trip.

Zhao Zhang Ph.D. — ZZ to just about everyone — is a bit of a scientific outlier.

Raphael Valdivia, professor of molecular genetics and microbiology at Duke, explores how tiny microbes found in the body—too small to see without a microscope—can be wielded to fight disease and to influence better health outcomes for all.

Fighting off bacterial pathogens that invade our own cells

Unlocking the secrets of aging and disease

A foundation of research enabling a quick pivot

About 38 million people worldwide are living with AIDS. Pharmaceutical treatments can keep the disease in check, but a vaccine remains elusive despite decades of concerted effort. However, a recent discovery at the Duke Human Vaccine Institute (DHVI) brings the goal of an effective vaccine within reach. 

Researcher and lymphoma survivor Kris Wood is finding answers.

A Bold New Effort Aims to Harness the Mechanisms of Resilience

What if we could supercharge our bodies to fight disease?

For most cancers, advances in genomics haven't changed treatment strategies very much. Sandeep Dave, M.D., M.S., envisions making personalized treatment a reality for more patients, by developing and making better use of tools that already exist.